COGNITION THERAPEUTICS INC 8-K

What Happened

• Cognition Therapeutics, Inc. (CGTX) filed a Form 8-K on March 2, 2026 (Item 8.01) and issued a press release announcing plans to advance development of its investigational drug zervimesine for the treatment of dementia with Lewy bodies (DLB) psychosis.
• The press release is furnished as Exhibit 99.1 to the 8-K.

Key Details

• Filing date: March 2, 2026 (Form 8-K, Item 8.01 — Other Events).
• Drug: zervimesine — indicated development focus on dementia with Lewy bodies psychosis.
• Disclosure: Announcement made via a press release included as Exhibit 99.1; the 8-K did not include financial terms, clinical data, or specific timelines.

Why It Matters

• This is a pipeline development update: it signals the company’s intent to advance a candidate (zervimesine) into further development for a specific neuropsychiatric indication (DLB psychosis).
• For investors, the item is material as a potential driver of future value tied to clinical progress, but the filing does not provide details on study plans, timing, funding, or results — additional company communications or regulatory filings will be needed for specifics.